AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients

  • AstraZeneca Plc AZN reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd).
  • The data showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR)-positive, HER2-low, or HER2-negative (IHC 0) unresectable or metastatic breast cancer. 
  • Safety results were consistent with previous trials of datopotamab deruxtecan. 
  • Also see: AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials.
  • In this cohort of TROPION-PanTumor01 (n=41), datopotamab deruxtecan demonstrated an objective response rate (ORR) of 27%. 
  • All responses were partial (n=11), and 56% of patients achieved stable disease (n=23). 
  • The disease control rate (DCR) was 85%, and the median progression-free survival (PFS) was 8.3 months. 
  • With a median follow-up of 13.7 months, the median duration of response (DoR) and the median overall survival (OS) had not been reached, with 59% of patients alive for more than one year.
  • Pivotal TROPION-Breast01 Phase 3 trial is ongoing, evaluating datopotamab deruxtecan in these patients in earlier lines of treatment.
  • Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo DSNKY and AstraZeneca.
  • Price Action: AZN shares closed higher by 0.46% at $69.17 on Thursday.
  • Photo Via Wikimedia Commons
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefsEurasia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!